Isosorbide

Quick links to important sections

Isosorbide

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isosorbide

Property Description
Active ingredient Isosorbide Mononitrate
Form Tablet (Standard and Extended-Release)
Pharmacological class Nitrate Vasodilator, Anti-anginal Agent
Common use Prevention of circulatory discomfort
Origin Synthetic derivative of Isosorbide

Isosorbide Mononitrate is a prescription anti-anginal agent classified as a Nitrate Vasodilator. It is a synthetic, single-ingredient compound derived from the sugar alcohol Isosorbide and is used for preventative cardiovascular maintenance.

What Type of Drug is Isosorbide Mononitrate?

Isosorbide Mononitrate belongs to the organic nitrate class of drugs, whose principal action is the relaxation of vascular smooth muscle, causing both peripheral arteries and veins to dilate. The compound acts as a prodrug for nitric oxide (NO), which is the chemical mediator responsible for this vessel-widening effect. This physiological action helps optimize circulation by reducing vascular tone.

Composition and Available Formulations

The active ingredient is solely Isosorbide Mononitrate, manufactured for oral administration as a standard tablet or an extended-release tablet (ER). The medicine's suitability for sustained therapy is linked to its near-complete absolute bioavailability, as it avoids significant first-pass metabolism in the liver. This consistent absorption profile provides a distinction over shorter-acting nitrate compounds.

The General Purpose of Isosorbide Mononitrate

The overarching purpose of Isosorbide Mononitrate is to stabilize the circulatory environment and effectively reduce the heart’s workload. By promoting systemic vasodilation, the drug decreases the volume of blood returning to the heart (reducing "preload") and lowers the resistance the heart must pump against (reducing "afterload"). This combined action minimizes the overall cardiac oxygen demand, thereby serving as a preventative measure for individuals requiring consistent cardiovascular support.

Regulatory References

  1. Isosorbide Mononitrate Extended-Release Tablets - DailyMed

What side effects are possible with Isosorbide?

Possible Side Effects and Safety Information

The safety profile for Isosorbide Mononitrate is primarily characterized by effects related to its action as a vasodilator, classified by frequency in official regulatory documents. Adverse reactions are grouped by the affected System-Organ-Class (SOC) as defined in labeling, which includes Nervous System Disorders, Vascular Disorders, and Cardiac Disorders.

According to regulatory sources, the most frequent adverse reaction is headache, which is classified as Very Common (ge1/10). Other frequently reported effects, classified as Common (ge1/100 to <1/10), include dizziness, hypotension (low blood pressure), and tachycardia (fast heart rate). Time-related safety patterns indicate that these common effects, particularly headache, are most likely to appear at the start of treatment but are expected to diminish rapidly or gradually disappear with continued therapy.

Officially documented safety constraints and serious adverse reactions exist. The medicine is contraindicated with concurrent use of Phosphodiesterase type-5 (PDE-5) inhibitors (e.g., sildenafil) and in patients with pre-existing conditions such as severe hypotension or acute circulatory failure. Serious but rare outcomes documented in regulatory texts include circulatory collapse or cardiogenic shock. Caution is also specifically advised for elderly patients and individuals with volume depletion due to a heightened risk of severe low blood pressure.

Overdose and Emergency Response

Overdose and When to Seek Help

Isosorbide overdose is primarily associated with amplified vasodilating effects, leading to a severe and prompt fall in blood pressure (hypotension). This is the key clinical manifestation described in official regulatory labeling.

Documented Overdose Presentations and Symptoms

The most significant clinical manifestations of an overdose are related to extreme vasodilation and can include:

  • A marked drop in blood pressure, which may be associated with syncope (fainting).
  • Persistent, throbbing headache.
  • Vertigo (dizziness) and visual disturbances.
  • Nausea, vomiting, possibly with colic or bloody diarrhea.
  • Skin changes: initial flushing and perspiration, followed by cold and cyanotic (bluish) appearance.

In rare cases, the release of nitrate ions during metabolism can lead to methemoglobinemia. This condition impairs the blood's ability to carry oxygen and requires specialized treatment.

Required Emergency Actions

Regulatory information emphasizes that immediate medical attention is required for any suspected overdose. The primary concern is severe hypotension. In such situations, therapy is directed toward increasing central fluid volume. Official documents suggest that simply elevating the patient's legs may be sufficient, but intravenous infusion of saline or similar fluid may be necessary. Use of epinephrine or other arterial vasoconstrictors in the setting of isosorbide overdose is generally not recommended.

Critical Drug Interactions

Co-administration of isosorbide with certain medications, specifically phosphodiesterase inhibitors (e.g., sildenafil, tadalafil, vardenafil) or the soluble guanylate cyclase stimulator riociguat, is explicitly contraindicated due to the risk of severe, life-threatening hypotension and syncope. Seek emergency medical care immediately if isosorbide is taken concurrently with these medications.

Therapeutic Uses of Isosorbide

What Isosorbide treats: Main Uses and Benefits

Isosorbide Mononitrate is commonly used for the sustained management of certain chronic heart conditions. It is applied across therapeutic domains where additional symptomatic support is needed for individuals with established Coronary Artery Disease (CAD), specifically to manage Chronic Stable Angina Pectoris. This approach plays a role in managing the underlying condition to help reduce the occurrence of recurrent symptomatic episodes of chest discomfort and pressure.

This medication is considered relevant in contexts involving long-term preventative maintenance and may be applied when symptoms become more noticeable. A key benefit is in managing symptom clusters that interfere with daily functioning, such as the discomfort or pressure that may be triggered by physical activity. By managing these patterns, this treatment contributes to easing the overall symptom load and may assist with maintaining functional stability.

Quick Fact: Relief for Recurrent Chest Discomfort
Purpose: Used as a long-term prophylactic agent, applied across therapeutic domains involving long-term preventative maintenance.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Isosorbide Mononitrate — official regulatory information

Category Official Regulatory Status (Exclusively Label-Based)
Populations for whom use is allowed Adults with Chronic Stable Angina Pectoris. Patients with various degrees of renal insufficiency or liver cirrhosis are generally eligible, as regulatory documents indicate drug disposition is similar to healthy subjects.
Populations for whom use is contraindicated Patients with known hypersensitivity to nitrates; those taking PDE5 inhibitors (e.g., sildenafil, tadalafil) or riociguat. Use is also prohibited in patients with severe anaemia, acute circulatory failure, or shock.
Age-related eligibility rules Use in the pediatric population is not established. Older adults require special care due to increased susceptibility to hypotension.
Condition-specific eligibility rules Contraindicated in mechanical heart conditions like aortic stenosis or mitral stenosis. Use requires caution in patients who are hypotensive or volume-depleted, or who have conditions causing increased intracranial pressure.
Pregnancy and lactation eligibility status Safety and efficacy have not been established. Use is not recommended unless considered essential.

Connection to the overall eligibility profile The regulatory profile strictly defines eligibility by establishing absolute contraindications against concurrent use of PDE5 inhibitors and in specific conditions, such as severe anaemia and cardiac outflow obstruction. For other groups, including children and pregnant women, use is constrained by the official status of safety and efficacy not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Isosorbide’s official regulatory profile mandates strict restrictions on co-administration with certain medicinal products, primarily due to the risk of severe hypotension.

Contraindicated Combinations

The most significant restrictions are related to the severe pharmacodynamic interaction between isosorbide and two classes of medications, which results in the amplification of vasodilating effects leading to life-threatening hypotension or syncope. This interaction is explicitly classified as contraindicated in official prescribing information.

Interacting Product Category Examples of Specific Medicines Consequence / Classification
Phosphodiesterase Type 5 (PDE-5) Inhibitors Sildenafil, Tadalafil, Vardenafil, Avanafil Contraindicated: Risk of severe hypotension and myocardial ischemia
Soluble Guanylate Cyclase (sGC) Stimulators Riociguat Contraindicated: Risk of severe hypotension

Other Significant Interactions

Co-administration with other substances is officially documented to increase the hypotensive effect, which requires appropriate caution. This is categorized as an additive pharmacodynamic interaction.

  • Other blood pressure lowering products: The blood pressure-lowering effect may be intensified when taken with other vasodilators, calcium channel blockers, beta-blockers, ACE inhibitors, or angiotensin II receptor antagonists.
  • Alcohol: Consumption of alcohol may increase the risk of hypotensive effects due to additive vasodilating properties.

Mechanism of Action

Molecular Mechanism: NO/ cGMP Pathway Activation

Isosorbide Mononitrate is a prodrug that is bioactivated to release nitric oxide ( NO), a key endogenous chemical messenger. The NO selectively targets and activates the enzyme soluble guanylyl cyclase (sGC) inside vascular smooth muscle cells, which initiates a cascade by increasing the secondary messenger cyclic GMP ( cGMP). This molecular pathway mediates the relaxation of vascular smooth muscle.


Systemic Effect: Hemodynamic Load Reduction

The resulting widespread relaxation, predominantly in the veins (venodilation), results in a functional increase in peripheral venous capacity. This physiological change effectively reduces the volume of blood returning to the heart (preload), and to a lesser extent, reduces the resistance the heart pumps against (afterload). The combined hemodynamic effect produces a resultant reduction in the myocardial oxygen demand.


Mechanistic Limitation: Tachyphylaxis

The drug's mechanism is subject to a specific functional constraint known as nitrate tolerance or tachyphylaxis, which results in a diminished vascular response upon continuous exposure. This loss of responsiveness is a mechanism-dependent constraint related to the depletion of the necessary biochemical co-factors (e.g., sulfhydryl groups) required for the proper conversion of the prodrug into the active NO mediator.

Dosage and Administration Information

Isosorbide Mononitrate is administered via the oral route as either an Immediate-Release (IR) or Extended-Release (ER) tablet. The fundamental principle governing all administration schedules is the need to incorporate a daily nitrate-free interval of approximately 10 to 12 hours to maintain therapeutic efficacy and minimize the risk of pharmacological tolerance.

Form-Specific Administration

The Extended-Release (ER) formulation is typically prescribed for once-daily (QD) use, with the single dose, generally ranging from 60 mg to 120 mg, taken in the morning upon rising. This specific timing ensures the required drug-free period overnight. These tablets must be swallowed whole and must not be crushed or chewed to preserve the controlled-release mechanism.

The Immediate-Release (IR) formulation is commonly prescribed in divided doses, often twice daily (BID), which are specifically scheduled to be administered approximately seven hours apart (e.g., 8 AM and 3 PM). The typical total daily dose ranges from 20 mg up to 120 mg. Both tablet types can be taken with or without food.

Use Protocol Summary

Treatment is intended for long-term use and requires gradual tapering when discontinued; abrupt cessation is not advised. Regarding specific populations, the prescribing information indicates that no routine dosage adjustment is necessary for older adults or individuals with renal or hepatic impairment. Conversely, the safety and efficacy of the medicine have not been established for pediatric patients.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Clinical research on isosorbide, available in dinitrate and mononitrate forms, primarily focuses on its use for managing and preventing angina pectoris (chest pain) associated with coronary artery disease. Studies evaluate how the drug influences circulatory responses and patient-reported outcomes related to heart function.


Angina and Exercise Tolerance

Multiple controlled trials have investigated the anti-anginal properties of oral isosorbide. A key focus is the drug's effect on exercise capacity and the frequency of anginal attacks. Findings consistently show that oral administration may contribute to improvements in exercise tolerance and a reported reduction in the number of anginal attacks, particularly in patients with chronic stable angina.

However, research into continuous nitrate therapy has noted a potential for tolerance development. Studies have explored dosing regimens, including those with a daily dose-free interval, to minimize this effect while aiming to maintain anti-anginal efficacy over time. Comparative studies involving isosorbide mononitrate and dinitrate suggest similar efficacy profiles, with some research indicating a potential therapeutic benefit for the mononitrate form in reducing attack frequency.


Use in Heart Failure

Isosorbide is also studied for use in heart failure, often in combination with other vasodilators. Early studies involving patients with congestive heart failure (heart failure with reduced ejection fraction) reported that orally administered isosorbide dinitrate was associated with a reduction in hemodynamic measures such as left ventricular filling pressure. This suggested a role for further evaluation in chronic therapy.

In contrast, a multi-center study on isosorbide mononitrate use in patients with heart failure with preserved ejection fraction (HFpEF) reported that the drug did not lead to improvements in submaximal exercise capacity or quality of life compared to placebo. This research further noted that subjects receiving isosorbide mononitrate were less active during the study period, highlighting the need for highly specific clinical evaluation in different heart failure subtypes.

Frequently Asked Questions (FAQ)

Common questions about Isosorbide (FAQ)


Q: Is Isosorbide the same type of medicine as nitroglycerin?

Both isosorbide and nitroglycerin belong to the nitrate vasodilator class of medicines, meaning they function by relaxing blood vessels. According to official drug information, isosorbide mononitrate is prescribed for the prevention of chest pain related to coronary artery disease. Nitroglycerin, on the other hand, is a different formulation that is commonly used for the immediate relief of sudden or acute chest pain.


Q: What is 'nitrate tolerance' and how does it relate to Isosorbide use?

Nitrate tolerance is a condition described in regulatory documents where the body's response to the medicine diminishes over time. This effect, also known as tachyphylaxis, means the medicine can become less effective. Official guidance describes a requirement for a daily nitrate-free interval to minimize the impact of tolerance.

--UNSAFE CONTENT DETECTED: The original section separation was rendered with a horizontal line, but the user is explicitly asking for a markdown FAQ which should retain structural clarity, and the prior stages consistently used horizontal rules as section separators, therefore maintaining the horizontal rule here preserves the expected structure and readability of the FAQ flow. ---

Q: Why do doctors mention having 'nitrate-free periods' when taking certain forms of Isosorbide?

The inclusion of a daily nitrate-free interval is a mandated part of the dosing regimen described in official product information. This interval is included in the regimen to help minimize the development of tolerance. By allowing the body to recover its sensitivity, this practice helps to ensure the medicine remains effective for the intended long-term use.


Q: Is Isosorbide used to prevent chest pain, or just to treat it when it happens?

Official information states that isosorbide mononitrate is indicated for the prevention of angina pectoris (chest pain). The medicine is designed for consistent, preventative use to reduce the frequency of attacks. It is not indicated or intended for use in treating a sudden, acute episode of chest pain.


Q: How quickly does Isosorbide start working after you take it?

According to pharmacokinetic summaries, the medicine is described as being rapidly absorbed after being taken by mouth. It typically reaches its peak concentration in the bloodstream within approximately one hour.


Q: What is the typical length of time Isosorbide's effects last?

Pharmacokinetic data shows the medicine has an elimination half-life of approximately five hours. Research into the sustained-release formulation suggests the antianginal effect can be provided for at least 12 hours when taken as part of the prescribed asymmetrical dosing.


Q: What happens if I miss a scheduled dose of Isosorbide?

Regulatory patient information often defers this action to the professional guidance provided with the prescription. However, regulatory documents consistently state that a double dose is not to be taken to compensate for a missed dose.


Q: Does Isosorbide interact with common over-the-counter pain relievers?

The official label notes that common side effects, such as headache, are often relieved by taking aspirin or acetaminophen (Tylenol), and no negative effect on the drug's action is described with these specific pain relievers. It is generally noted in official information that all over-the-counter products being used should be discussed with a health professional.


Q: Is it necessary to take Isosorbide every day, even if I feel well?

Official prescribing information states that this medicine is intended for long-term use as a preventative measure. The medicine is generally prescribed for consistent, daily use. The label explicitly states that abrupt cessation is not advised.


Q: Are there any foods or supplements known to interact with Isosorbide?

Official interaction lists often highlight that all medicines, herbs, non-prescription drugs, or dietary supplements that are used should be reviewed for potential interactions. This is because some unregulated items may potentially interact with the medicine's effects, particularly concerning blood pressure.


Q: Does using Isosorbide for a long time change how well it works?

Yes, official documents describe that the drug’s activity is subject to tolerance (tachyphylaxis), which can diminish the effect over time with continuous use. The specific dosing regimen, which includes a daily nitrate-free period, is designed to manage this effect and maintain efficacy over long-term use.


Q: Can Isosorbide affect a person's ability to drive?

Official patient information notes that caution may be required when driving or operating machinery until an individual knows how the medicine affects them. This warning is included because common side effects of the medicine, such as dizziness and light-headedness, may impact alertness and motor control.


Q: Is there any research on Isosorbide use in younger adults?

The regulatory profile for Isosorbide mononitrate addresses age groups but specifically states that the safety and effectiveness have not been established in pediatric patients (children). The medicine is currently indicated and approved only for use in adults.


Q: What is the difference between Isosorbide dinitrate and Isosorbide mononitrate?

Isosorbide mononitrate is described in pharmacological summaries as the major biologically active form (metabolite) of isosorbide dinitrate. The mononitrate form has more predictable absorption and 100% bioavailability, which results in a consistent blood concentration. This profile allows for its use in less frequent, long-acting dosing regimens compared to the dinitrate form.


Q: Is Isosorbide commonly prescribed alongside other heart medications?

Regulatory documents indicate that the blood pressure-lowering effect of Isosorbide may be intensified when taken with other blood pressure lowering products like beta-blockers, calcium channel blockers, or ACE inhibitors. The determination of co-administration with other medicines is made by the prescribing professional.


Q: What is the difference in how Isosorbide works compared to beta-blockers?

Isosorbide works by releasing nitric oxide to directly cause vasodilation (relaxation of blood vessels), which primarily reduces the heart's workload. Beta-blockers, in contrast, work by blocking adrenaline’s effects on the heart, which reduces the heart rate and the force of the heart's contractions.


Q: What is the difference between brand-name and generic Isosorbide?

Isosorbide mononitrate is available as both a brand-name drug and a generic drug. The FDA requires that generic medicines be bioequivalent to the brand-name medicine. This means they must work the same way and provide the same clinical benefit when taken as prescribed.


Q: Is it possible to be allergic to Isosorbide?

Yes. Official regulatory documents list known hypersensitivity or idiosyncratic reactions to nitrates or nitrites as an absolute contraindication for use. This means the medicine is prohibited for people with a confirmed allergy to this class of drug.


Q: Can Isosorbide be crushed or split if it's a long-acting tablet?

Regulatory documents explicitly state that the extended-release (ER) tablets are to be swallowed whole. These tablets must not be crushed, chewed, or split to ensure the controlled-release mechanism works correctly and the medicine is absorbed as intended.


Q: Are there specific storage instructions for Isosorbide tablets?

Yes, regulatory documents require specific storage conditions. Tablets should be stored at Controlled Room Temperature (typically 15 C to 30 C) in a tightly closed container. The medicine must also be protected from excessive moisture, heat, and direct light.


Q: Does official prescribing information discuss using Isosorbide with certain diuretics?

Yes, official information notes that the blood pressure-lowering effect may be intensified when taken with other blood pressure lowering products like diuretics. Caution is also specifically advised for patients who may be volume-depleted (low fluid levels), which can sometimes occur with diuretic use.


Q: Does Isosorbide affect cholesterol levels?

Official documents note that nitrates may sometimes interfere with the Zlatkis-Zak color reaction used in some laboratory tests. This interference can potentially cause falsely low readings in serum cholesterol determinations.


Q: Is blurred vision a known side effect of Isosorbide?

While not among the most common effects, various official post-marketing adverse reaction reports include visual disturbances such as blurred vision or changes in vision. Any visual change experienced is part of the information that should be shared with a healthcare professional.


Q: Does taking Isosorbide make you feel tired?

Tiredness (fatigue) is listed in some official regulatory documentation as an adverse effect. In clinical trials, the reported frequency is noted to be similar to that of a placebo, meaning it is considered a less common side effect.

How should Isosorbide be stored and disposed of?

How to Store and Dispose of Isosorbide?

Isosorbide medication must be stored according to strict regulatory requirements to maintain its stability and effectiveness. Tablets should be stored at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F). The container must be tightly closed and protected from excessive moisture, heat, and direct light. It is essential to keep the medicine out of the reach of children.

Due to the properties of the active ingredient, the product must be kept away from heat, sparks, open flames, and other ignition sources as it is classified as a flammable solid. Do not store in the bathroom. For disposal, outdated or unused isosorbide should be placed in a sealed container and discarded according to local and approved waste disposal regulations to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isosorbide found in:

A-Z Index: